Key result
Atorvastatin /d reduces recurrent ischemic events in ACS, driven by fewer rehospitalizations for ischemia.
Why the study?
Does atorvastatin 80 mg/d reduce recurrent ischemic events in patients with acute coronary syndrome?
Does atorvastatin 80 mg/d reduce recurrent ischemic events in patients with acute coronary syndrome?
Early initiation of high-dose atorvastatin (80 mg/d) in patients with acute coronary syndrome reduces recurrent ischemic events within 16 weeks.
Answers are grounded in this paper and cite their sources.
Supports early high-dose atorvastatin initiation in ACS; confirms benefit of intensive lipid-lowering in the acute phase.
For patients with acute coronary syndrome, lipid-lowering therapy with atorvastatin, 80 mg/d, reduces recurrent ischemic events in the first 16 weeks, mostly recurrent symptomatic ischemia requiring rehospitalization.
No takes yet. Share an insight, caveat, or question.
Gregory G. Schwartz (2001) studied this question. Atorvastatin /d reduced recurrent ischemic events, mostly recurrent symptomatic ischemia requiring rehospitalization, within the first 16 weeks in patients with acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: